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Background: The emergence of Plasmodium falciparum resistance to artemisinins in Southeast Asia threatens the
control of malaria worldwide. The pharmacodynamic hallmark of artemisinin derivatives is rapid parasite clearance
(a short parasite half-life), therefore, the in vivo phenotype of slow clearance defines the reduced susceptibility to
the drug. Measurement of parasite counts every six hours during the first three days after treatment have been
recommended to measure the parasite clearance half-life, but it remains unclear whether simpler sampling intervals
and frequencies might also be sufficient to reliably estimate this parameter.
Methods: A total of 2,746 parasite density-time profiles were selected from 13 clinical trials in Thailand, Cambodia,
Mali, Vietnam, and Kenya. In these studies, parasite densities were measured every six hours until negative after
treatment with an artemisinin derivative (alone or in combination with a partner drug). The WWARN Parasite
Clearance Estimator (PCE) tool was used to estimate “reference” half-lives from these six-hourly measurements. The
effect of four alternative sampling schedules on half-life estimation was investigated, and compared to the
reference half-life (time zero, 6, 12, 24 (A1); zero, 6, 18, 24 (A2); zero, 12, 18, 24 (A3) or zero, 12, 24 (A4) hours and
then every 12 hours). Statistical bootstrap methods were used to estimate the sampling distribution of half-lives for
parasite populations with different geometric mean half-lives. A simulation study was performed to investigate a
suite of 16 potential alternative schedules and half-life estimates generated by each of the schedules were
compared to the “true” half-life. The candidate schedules in the simulation study included (among others) six-hourly
sampling, schedule A1, schedule A4, and a convenience sampling schedule at six, seven, 24, 25, 48 and 49 hours.
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Results: The median (range) parasite half-life for all clinical studies combined was 3.1 (0.7-12.9) hours. Schedule A1
consistently performed the best, and schedule A4 the worst, both for the individual patient estimates and for the
populations generated with the bootstrapping algorithm. In both cases, the differences between the reference and
alternative schedules decreased as half-life increased. In the simulation study, 24-hourly sampling performed the
worst, and six-hourly sampling the best. The simulation study confirmed that more dense parasite sampling
schedules are required to accurately estimate half-life for profiles with short half-life (≤three hours) and/or low initial
parasite density (≤10,000 per μL). Among schedules in the simulation study with six or fewer measurements in the
first 48 hours, a schedule with measurements at times (time windows) of 0 (0–2), 6 (4–8), 12 (10–14), 24 (22–26),
36 (34–36) and 48 (46–50) hours, or at times 6, 7 (two samples in time window 5–8), 24, 25 (two samples during
time 23–26), and 48, 49 (two samples during time 47–50) hours, until negative most accurately estimated the “true”
half-life. For a given schedule, continuing sampling after two days had little effect on the estimation of half-life,
provided that adequate sampling was performed in the first two days and the half-life was less than three hours.
If the measured parasitaemia at two days exceeded 1,000 per μL, continued sampling for at least once a day was
needed for accurate half-life estimates.
Conclusions: This study has revealed important insights on sampling schedules for accurate and reliable estimation
of Plasmodium falciparum half-life following treatment with an artemisinin derivative (alone or in combination with
a partner drug). Accurate measurement of short half-lives (rapid clearance) requires more dense sampling schedules
(with more than twice daily sampling). A more intensive sampling schedule is, therefore, recommended in locations
where P. falciparum susceptibility to artemisinins is not known and the necessary resources are available. Counting
parasite density at six hours is important, and less frequent sampling is satisfactory for estimating long parasite
half-lives in areas where artemisinin resistance is present.
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Anti-malarial drug resistance poses a serious threat to glo-
bal efforts to control and eliminate malaria. During the
1980s and 1990s, malaria-related mortality increased due to
the spread of Plasmodium falciparum resistance to anti-
malarial drugs. This trend was reversed by replacing failing
drugs with highly efficacious artemisinin-based combin-
ation therapy (ACT) and deployment of improved vector
control measures. ACT is now the recommended first-line
treatment for P. falciparum malaria in almost all endemic
countries [1,2]. In the past, parasite resistance to chloro-
quine and then to sulphadoxine-pyrimethamine spread
from Western Cambodia throughout Asia and Africa. The
recent emergence of artemisinin resistance in P. falciparum
malaria on the Thailand-Cambodia border therefore poses
a considerable global health threat [3-5].
To date, the molecular basis of artemisinin resistance
has not been elucidated and conventional in vitro drug
response assays have provided conflicting results. Re-
cently, a ring stage survival assay has been proposed, but
it requires specific skills, training and validation [6,7].
Strong evidence of artemisinin resistance in Southeast
Asia was recognized by the significant reduction in the
parasite clearance rate following artesunate treatment
and increased failure rates following ACT administration
[4,8,9]. Until a definitive molecular marker is identified
and validated in various regions, accurate and reliable
measurement of parasite clearance remains a robustand simple method of assessing the spread or independent
emergence of artemisinin-resistant P. falciparum in
Southeast Asia and elsewhere. Furthermore, parasite
clearance is becoming an essential component of the
measurement of the efficacy of new anti-malarials.
Following treatment with an effective anti-malarial
drug, the clearance of parasites from the peripheral
blood is proportional to the parasite density (that is, a
first-order process) [10,11]. As such, the predominant
relationship between the log-transformed parasite dens-
ity and time is generally linear [12-14]. The slope of
the log-parasitaemia versus time relationship is con-
sidered the most robust measure of parasite clearance
[15], and of various different in vivo measures shows
the highest heritability among P. falciparum parasites
in a setting where artemisinin resistance is prevalent
[16]. However, several potential sources of error can
be introduced if a straight line is fitted to all log-
parasite density data [14]. Previous estimates of para-
site clearance rates have, therefore, been complicated
by observer subjectivity in how to handle these
sources of variation [14,15].
To facilitate the standardized and accurate estimation
of parasite clearance rates, the WorldWide Antimalarial
Resistance Network (WWARN) previously developed
the Parasite Clearance Estimator (PCE) tool, now avail-
able online [14,17]. The PCE expresses parasite clear-
ance in terms of the slope half-life and has been used to
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(for example, [18-21]). Using this tool, parasite clearance
distributions may be compared from different study lo-
cations and times, where half-life distributions that are
centered around smaller half-lives correspond to a rela-
tively sensitive response compared to distributions cen-
tered at longer half-life values. For example, the parasite
clearance distribution in Pailin, Cambodia, in 2008–2010
showed evidence of slow clearance with a median half-
life of 5.8 hours [21] while the distribution in Mali in
2010 showed evidence of a sensitive response (median
half-life of 1.9 hours) [19].
In order to accurately estimate parasite clearance using
the current version of the PCE tool, frequent parasite
counts (at least twice daily) are recommended. However,
most in vivo assessments published in the literature
measure parasitaemia either daily, or only on days D0,
D2 and D3, as recommended by the World Health
Organization [22]. The proportion of patients with de-
tectable parasitaemia on D3 is a simple measure of para-
site clearance at the population level [23], and provides a
useful metric of response that can be widely applied.
However, “D3-positivity” at the individual patient level is
inaccurate because it depends heavily on the pre-
treatment parasite density and the precise timing of
sampling, and these can vary substantially within and
across clinical trials. D3 can correspond to a time ran-
ging from 60 to 80 hours after treatment, depending on
the time of patient enrolment and the subsequent
follow-up visits. For example, a patient first treated at
09.00 on D0 may be assessed for parasitaemia at 17.00
on D3 (80 hours later).
To compare parasite clearance rates across different
study sites and times, frequent parasite counts are
needed to generate accurate and reliable estimates. This
method is dependent on resource and operational con-
straints, capacity to generate quality-assured parasite
density counts, and patient convenience (in terms of
how often blood samples are taken), all factors that may
limit the number of measurements that can be taken at
a given site. In fact, the six hourly schedule was arbitrar-
ily defined, and there have been no studies validating
that these measurements need to be, or indeed should
be, collected at regular time-intervals to best facilitate
clearance estimation. Schedules that produce accurate
rate estimates yet minimize patient (and/or their care-
takers) inconvenience (including hospitalization and
night-time blood collection) would clearly be preferable.
Here, the effects of potential alternative sampling sched-
ules on the estimation of parasite clearance rates were
investigated using real patient data from 13 studies with
a combined sample size of 4,652 patients, conducted
between 2001 and 2011 in Cambodia, Thailand, Mali,
Kenya and Vietnam.Methods
This paper used three approaches to investigate the ef-
fect of different sampling schedules on parasite clearance
estimates. The first approach used a large dataset of pa-
tient data, pooled across 13 studies conducted between
2001 and 2011, to compare the HL estimates from four
alternative sampling schedules. The second used statis-
tical bootstrap method to investigate the effect on popu-
lation estimates of HL when the same four alternative
schedules were applied to populations that varied from
short to very long geometric mean HL. In the final ap-
proach, a simulation study was designed in which para-
site counts were generated so that more complicated
sampling schedules could be assessed.
Study data
This work was conducted by the Parasite Clearance
Study Group, under the auspices of WWARN, as part of
a larger effort to combine all available data from ACT
efficacy studies that measured parasite densities at least
twice daily. Parasite density-time profiles from published
and unpublished studies that measured six-hourly para-
site densities were sought for this analysis. Studies were
identified among those that used the PCE tool and
through calls for data at international meetings. Only
studies in which patients were treated with artesunate
alone or in combination with a partner drug were con-
sidered. Within each study, only patients with parasite
densities measured every six hours until parasitaemia
became undetectable (i.e., “negative”) on blood smears
were included.
Thirteen datasets fulfilled these inclusion criteria and
all had one of three sampling schedules (Table 1). The
most common schedule was every six hours until nega-
tive (SS1). The second most common sampling method
was zero, two, four, six, eight and 12 hours and then
every six hours until negative (SS2). The schedule for
one study (Thailand2) was zero, four, eight and 12 hours
and then every six hours until negative (SS3). This latter
study, which did not meet the inclusion criterion of
reporting parasite density at six hours, was nevertheless
included and the parasite density at four hours used in
the analysis instead. Since the exact times of blood sam-
pling varied slightly between studies, measurements
made every six ± one hour were considered acceptable
for inclusion. Seven studies counted parasites using both
thin and thick smears, either per 1,000 red blood cells
(RBC) and 500 white blood cells (WBC), 1,000 RBC and
400 WBC, 1,000 RBC and 200 WBC or 5,000 RBC and
200 WBC (Table 1). In five studies, parasites were
counted per 200 WBC or 300 WBC in thick smears
only. The actual times of blood sampling were recorded
in all studies and were used in the present analysis to es-
timate parasite clearance.





Counting method DLM Reference
Thick (WBC) Thin (RBC)
Thailand1 2001-2010 3391 SS1 500 1000 16 Phyo et al. [20]
Thailand2 2008 40 SS3 200 1000 16 Dondorp et al. [4]
Thailand3 2009-2010 80 SS2 200 1000 16 Das et al. [21]
Mali 2010 261 SS1 300 ND 25 Lopera-Mesa et al. [19]
Cambodia1 2007-2008 59 SS2 200 1000 16 Dondorp et al. [4]
Cambodia2 2008-2010 79 SS2 200 1000 16 Das et al. [21]
Cambodia3 2009 79 SS1 200 ND 15 Amaratunga et al. [18]
Cambodia4 2010 98 SS1 200 ND 15 Amaratunga et al. [18]
Cambodia5 2010 30 SS1 200 ND 15 Amaratunga et al. [18]
Cambodia6 2010 55 SS1 200 ND 15 Unpublished
Cambodia7 2008-2009 143 SS2 200 5000 14 Bethell et al. [24]
Kenya 2010-2011 171 SS2 30 Unpublished
Vietnam 2010-2011 166 SS1 400 1000 8 Hien et al. [25]
Total 4652
SS1 = six-hourly until negative; SS2 = zero, two, four, six, eight and 12 hours, and then six-hourly until negative; SS3 = zero, four, eight and 12 hours, and then
six-hourly until negative; ND = not done; DLM = detection limit of microscopy (in parasites per μL); RBC = red blood cells; WBC = white blood cells.
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As a measure of parasite clearance, the parasite half-life
(HL) was calculated for each patient’s parasite density-
time profile, using WWARN’s PCE tool. A schematic of
the parasite clearance profile is shown in Figure 1. The
PCE selects the most appropriate model (linear, quad-
ratic or cubic) to fit the log-transformed parasite dens-
ities. The model then detects when a “lag-phase” is
present (ie, the initial part of the profile having a much
flatter slope than the remaining part of the profile). The
HL is then calculated, based on the slope of the linearFigure 1 Schematic representation of the WWARN Parasite
Clearance Estimator model of parasite clearance.part of the curve, adjusted for this lag-phase. The “tail”
of the profile (if present), defined as the terminal part of
the profile when parasitaemia remains close to the limit
of detection and does not decrease over a number of
time-points, is excluded before parasite clearance is esti-
mated. Using this method, the parasite clearance esti-
mate is independent of the initial parasite density since
the rate of clearance is measured rather than the time to
clearance. Departing from previous approaches, parasite
counts below the limit of detection are accounted for
using tobit regression [26] and are not excluded from
the model. The PCE model is detailed in [14] and has
been recently validated [16].
Approach 1: Effect of alternative sampling schedules on
estimation of half-life
A common sampling schedule used in clinical studies in
the field is 12-hourly sampling; however, if the parasite
clearance profile has a lag-phase, this schedule may be
unable to detect it (Figure 1). The effect of adding add-
itional observations in the first 24 hours to the 12-hourly
sampling schedule was investigated. For each patient in-
cluded in the analysis, a reference (“true”) HL was calcu-
lated using parasite densities measured every six hours
until the first negative parasitaemia. Four alternative sam-
pling schedules (Table 2) were investigated and the HL es-
timates obtained for these schedules were compared to
the reference HL estimates. Alternative schedules A1, A2
and A3 included four parasite densities in the first
24 hours, excluding a measurement at 18, 12 or six hours,
respectively. After 24 hours, data points were included
every 12 hours until the first negative parasitaemia.
Table 2 The sampling time-points (in hours) included in the reference schedule and each of the four alternative
schedules, A1-A4, for the analysis of real patient data
Sampling schedule 0 6 12 18 24 30 36 42 48 Every 6 hours until negative Every 12 hours until negative
Reference X X X X X X X X X X
A1 X X X X X X X
A2 X X X X X X X
A3 X X X X X X X
A4 X X X X X X
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the whole sampling period. For each of the patient pro-
files, the relative difference in HL for each alternative sam-
pling schedule was defined as:
HL relative difference ¼ SS HL ‐ R HL
R HL
 100%;
where SS_HL and R_HL are the HL estimates for the al-
ternative and reference sampling schedules, respectively.
The difference in HL was defined as:
HL difference ¼ SS HL ‐ R HL:
The proportions of profiles that were misclassified
when the HL estimates were dichotomized using cut-off
HL values of three, four, five and six hours were also re-
ported. That is,
Proportion misclassified ¼ proportion profiles with SS HL
> cutoff and R HL < cutoff
þ proportion profiles with SS HL
< cutoff and R HL > cutoff
Approach 2: Sampling distribution of half-life with
bootstrapping
To study the effect of different sampling schedules on
population estimates of HL for different geometric mean
HL, a bootstrapping algorithm with replacement (see for
example, [27]) was adopted whereby 100 patients were
randomly selected from the reference dataset to form a
theoretical cohort and the sampling procedure was re-
peated 1,000 times. When 100 patients were selected
from the reference dataset, the same 100 patients cre-
ated the datasets for the four alternative schedules. The
effect of each schedule was evaluated by examining the
distribution of the median HL estimates and the propor-
tion of profiles with a HL above three, four, five and six
hours. Bootstrap samples were selected from the whole
reference dataset itself so that the HL followed a pre-
specified log-normal distribution (HL ~ logN (μ,sd2) as
follows. Given the reference geometric mean HL (M)
and the coefficient of variation (CV), the parameters of
the log-normal distribution were calculated: μ ¼ loge Mð Þand sd ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
loge CV
2 þ 1 
q
. For each bootstrap sample,
j = 1 to 1000, the following steps were completed:
a) segmented the reference HL distribution into
discrete sections, Si, i = 1…r. The segments were
each of one hour width from zero hours to 13 hours
(the range of HL is 0.7-12.9).
b) selected one of the r segments from (a), chosen at
random.
c) identified reference HLs from the real data that lie
within the rth segment, chosen in (b).
d) sampled one of the reference HLs identified in (c),
chosen at random.
e) accepted the reference HL as the jth bootstrap
sample with a probability p, where p is the log-
normal density for the given values of M and CV,
for the HL chosen in (d).
f ) repeated steps (a) – (e) until 100 patients had been
accepted into the jth bootstrap sample.
Geometric mean (M) HLs of two, three, four, five, six
and seven hours and CVs of 20, 30, 40 and 50% were
considered. For each combination of M and CV, 1,000
bootstrap samples (each of 100 patients) were sampled
from the reference HL distribution (and subsequently
from the alternative schedule HL distributions). The
relative difference in median HL from the bootstrap
samples for each alternative sampling schedule was de-
fined as:
relative difference in median HL
¼ median SS HL ‐ median R HL
median R HL
 100%;
where ‘median SS_HL’ and ‘median R_HL’ are the me-
dian HL estimates for the alternative and reference sam-
pling schedules, respectively.
Approach 3: Comparison of sampling schedules on
simulated data
To investigate more complicated sampling schedules
that included a time-point not represented in the refer-
ence schedule, a simulation study was designed. Parasite
counts were generated based on the variability observed
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realistic. The process by which parasite count data
were generated, for a given HL and P0, is presented in
Additional file 1. For a specified “true” HL and “true” ini-
tial parasitaemia (P0), 1,000 log-parasite density-time pro-
files were generated, and the HLs using a number of
different sampling schedules (Table A2.1 in Additional
file 2) were calculated using the PCE tool. These include
regular sampling schedules (S1-S4), the best sampling
schedule from the bootstrap analysis (B1 = A1), an optimal
sampling schedule [28], schedules based on once daily
repeated sampling (M1-M3) and slight modifications of
these schedules. All combinations of “true” HLs of two,
three, four, five and six hours and “true” initial parasite
densities (P0) of 5,000, 10,000, 50,000, 100,000, and
200,000 per μL were examined. The effect of the sampling
schedules on estimates of HL was assessed through com-
parisons with the “true” HL using the proportion of pro-
files with an absolute value of relative difference (ARD)
more than 10, 20 and 30% and the proportion of profiles
with an absolute value of difference (AD) greater than one
hour. For the two sampling schedules that stopped at
48 hours (O1 and S1c), large values of the HL and high P0
combinations could result in a final parasite density ex-
ceeding 1,000 per μL, in which case a HL estimate is not
typically available through the PCE tool [14]. To facilitate
comparison of these two schedules, the PCE tool was ad-
justed and run separately for these two schedules such
that the HL was estimated, regardless of what was the
parasite density at 48 hours.
Results
Study data
The 13 studies that satisfied the inclusion criteria
(Table 1) have a combined sample size of 4,652 patients,
and were conducted in Cambodia (n = 7), Thailand (n = 3),
Mali (n = 1), Kenya (n = 1) and Vietnam (n = 1) between
2001 and 2011. The sample size and detection limit of mi-
croscopy for each study are summarized in Table 1. In the
13 studies, 2,746 patients satisfied the inclusion criteria of
regular six-hourly parasite density counts and were in-
cluded in the reference dataset and analysis (Table 3).
Parasite clearance parameters
The median, range and interquartile range (IQR) of
parasite HLs for individual studies and all studies com-
bined are presented in Table 3. The median (range) HL
of all studies was 3.1 hours (0.7-12.9) and varies between
studies, ranging from 1.9 hours to 7.0 hours. The pro-
portion of profiles with a non-zero lag-phase (tlag) was
26.5% for all studies, and ranged from six to 58%
(Table 3). Of those profiles with a non-zero tlag, the
median lag-phase duration of all studies was six hours,
and ranged from four to 15 hours. The coefficient ofvariation of HL estimates for all studies was 54%, and
ranged between 26 and 59%. The proportion of profiles
showing a tail (i.e., the terminal part of the profile when
parasitaemia remains close to the detection limit) for all
studies was 34% and between 0 and 57% in individual
studies.
Approach 1: Effect of alternative sampling schedules on
estimation of half-life
The effect of using alternative schedules A1, A2, A3 and
A4 to estimate parasite clearance was assessed first on
the 2,746 real patient profiles. The median (IQR) differ-
ence in HL estimates between the reference and alter-
native sampling schedules was 0.01 (−0.15-0.21), 0.06
(−0.10-0.29), 0.09 (−0.09-0.34) and 0.15 (−0.06-0.46)
hours, for A1, A2, A3 and A4, respectively (Table 4).
Overestimation of the HL by the alternative schedule
(i.e., when the HL from the alternative schedule exceeded
the reference HL) occurred in 50, 60, 60 and 66% of pro-
files using the A1, A2, A3 and A4 schedules, respectively.
If there were no systematic bias in the estimation of HL,
then on average overestimation would occur in 50% of
samples. A zero lag phase (tlag) under the alternative
schedule and a difference in the use of tobit regression
were both causes of overestimation of the HL under the
A1-A4 schedules, compared to the reference schedule
(Table A3.1, Additional file 3).
The 12-hourly schedule (A4) was the worst performing
schedule when the real patient data were used. The main
determinants of the discrepancy between the reference
and A4 schedules were the presence of a lag-phase in
the reference profile and a small number of measure-
ments, which resulted in a simple regression model fit-
ted for the A4 schedule (with the first zero replaced by
the detection limit) as opposed to a tobit regression fit-
ted for the reference data (Table A3.2, Additional file 3).
A six-hour delay in the time when the first negative
parasitaemia was recorded (when using A4 versus the
reference schedule) did not matter overall.
The difference between HLs estimated by the alterna-
tive and reference schedules was greater for profiles
with a short reference HL (compare HL > 4 and HL ≤ 2 in
Figure 2) and could have a considerable effect on the esti-
mates of the distribution of HL in a study. The misclassifi-
cation of profiles was highest for a cutoff value of HL of
three hours (7.7, 8.6, 9.5 and 10%, respectively for A1, A2
A3 and A4) (Table 4).
Approach 2: Sampling distribution of half-life with
bootstrapping
The effect of using alternative schedules A1-A4 on
population estimates of HL from a log-normal distribu-
tion with pre-specified geometric mean HL and coeffi-
cient of variation was assessed using bootstrap methods.
Table 3 Summary of results from 13 included studies
Country Proportion of patients Median HL; range; IQR CV (%) Std dev log(HL) Prop NZ tlag Median NZ tlag Prop with tail
Thailand1 46% (1571/3391) 3.05; 0.889-12.9; 2.37-4.24 46.4 0.438 26.4% (n = 415) 6 42.1% (n = 662)
Thailand2 82% (33/40) 2.87; 1.48-7.54; 2.11-3.77 46.8 0.421 18.2% (n = 6) 4.05 54.5% (n = 18)
Thailand3 88% (70/80) 3.26; 0.964-9.09; 2.36-4.42 50.4 0.49 24.3% (n = 17) 6 41.4% (n = 29)
Mali 99% (258/261) 1.87; 0.678-4.27; 1.57-2.34 30.0 0.296 58.1% (n = 150) 6 1.55% (n = 4)
Cambodia1 97% (57/59) 6.11; 2.53-9.5; 4.93-7.18 26.1 0.285 21.1% (n = 12) 12 45.6% (n = 26)
Cambodia2 94% (74/79) 5.79; 2.07-9.37; 4.85-7.32 31.1 0.359 24.3% (n = 18) 6.02 40.5% (n = 30)
Cambodia3 99% (78/79) 6.09; 1.71-11.2; 4.69-7.15 32.4 0.377 7.69% (n = 6) 6 14.1% (n = 11)
Cambodia4 100% (98/98) 6.5; 2.13-11.3; 5.14-7.73 29.2 0.329 6.12% (n = 6) 15 2.04% (n = 2)
Cambodia5 100% (30/30) 5.75; 2.66-10.5; 4.12-7.48 34.5 0.363 33.3% (n = 10) 15 13.3% (n = 4)
Cambodia6 78% (43/55) 2.62; 1.13-4.43; 2.31-3 25.9 0.278 6.98% (n = 3) 6 27.9% (n = 12)
Cambodia7 98% (140/143) 7.03; 1.7-11.8; 5.6-8.11 31.6 0.397 6.43% (n = 9) 6 57.1% (n = 80)
Kenya 93% (159/171) 2.49; 0.956-5.19; 1.89-3.09 33.1 0.354 19.5% (n = 31) 6 0% (n = 0)
Vietnam 81% (135/166) 2.9; 1.02-10.2; 2.04-5.46 59.3 0.572 34.1% (n = 46) 6.23 40.7% (n = 55)
Total 59% (2746/4652) 3.13; 0.678-12.9; 2.29-5 53.8 0.519 26.5% (n = 729) 6 (6–6.25) 34% (n = 933)
For each of the studies, country; proportion of total patients included; median HL (range; IQR); coefficient of variation (CV) as a percentage; standard deviation of
log (HL); proportion of profiles with a non-zero tlag; the median tlag for the profiles with a non-zero tlag; and the proportion of profiles with a tail. The bottom
row gives the corresponding values for the pooled dataset. IQR = interquartile range; NZ = non-zero; prop = proportion.
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mated (median (range) relative difference) the median
HL by 2.3% (−9.1-40.6). Here overestimation refers to
the proportion of bootstrap samples in which the me-
dian HL from an alternative schedule exceeded the me-
dian HL from the reference schedule. Overestimation
increased significantly in the 12-hourly schedule (A4)
and in bootstrap datasets with a geometric mean HL of
two hours (Figure 3). In this worst-case scenario (i.e., A4
schedule, HL = 2 hours), the median (range) relative dif-
ference in median HL was 26.0% (9.1-40.6) (Figure 3D).
Estimation of the median HL was not affected by the
CV of the datasets.
Examining the estimates of the proportion of profiles
with a HL above a value of three, four, five and six
hours, of all the alternative schedules applied to all boot-









Ref 0% 0 (0–0) 54.5 0.52 26.5 (n =
A1 49.9% 0.01 (−0.15-0.21) 51.6 0.503 22.1 (n =
A2 60.2% 0.06 (−0.10-0.29) 51.1 0.482 17.4 (n =
A3 59.8% 0.09 (−0.09-0.34) 50.9 0.484 12.5 (n =
A4 66.3% 0.15 (−0.06-0.46) 47.7 0.435 6.96 (n =
For each of the reference and alternative schedules (A1-A4) applied to real patient
reference HL); median difference in HL (IQR); coefficient of variation of HL (CV) as a
non-zero lag phase (tlag); the median (IQR) tlag for profiles with a non-zero tlag; th
misclassified when the HL estimates are dichotomized using HL cut-offs of three, four,
(proportion of HLs from alternative schedule which exceeded reference HL); NZ = non-estimates of these proportions by absolute 10% differ-
ence or more. Of these, 7,224 (91%) occurred when the
HL was above three hours. Among these profiles, 69%
were for bootstrap samples with a geometric mean HL
of two hours and 30% for a geometric mean HL of three
hours, and <1% for all other HL.
The 12-hourly schedule (A4) was also the worst per-
forming schedule in the bootstrap analysis. The 12-
hourly A4 schedule overestimated the proportion of pro-
files with a HL above three hours by 10% or more in
56% of bootstrap samples with a geometric mean HL of
two hours and 31% for a geometric mean HL of three
hours. These proportions were significantly lower for the
other three alternative schedules: 13 and 4% for A1; 22
and 6% for A2 and 33 and 13% for A3. Estimation was
only slightly affected by the CV. Comparing the propor-
tions of profiles with a HL greater than three hourshedules
Median (IQR)
NZ tlag
Prop tail Prop (%) profiles misclassified,
with HL cutoff of:
3 h 4 h 5 h 6 h
729) 6 (6–6.25) 34% (n = 933) 0 0 0 0
606) 6 (6–6.27) 9.36% (n = 257) 7.7 3.9 2.7 2.2
478) 6 (6–6.03) 9.87% (n = 271) 8.6 4.4 3 2.2
344) 12 (12–12) 9.91% (n = 272) 9.5 4.5 3 2.1
191) 12 (12–12) 9.25% (n = 254) 10 4.6 3.4 2.2
data: the proportion of profiles that overestimate the HL (relative to the
percentage; standard deviation of log (HL); the proportion of profiles with a
e proportion of profiles with a tail and the proportions of profiles that are
five and six hours. IQR = interquartile range; Ref = reference; OE = overestimation
zero; prop = proportion.
Figure 2 Relative difference (%) in half-life between alternative schedules A1-A4 and the reference dataset (six-hourly sampling), using
actual study data. See Table 1 for a list of 13 included studies. Boxplots show the median, interquartile range and range. Panels A, B, C and D
correspond to HLs less than 2 hours, between 2-3 hours, between 3-4 hours and more than 4 hours, respectively.
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the four alternative schedules (compared to the refer-
ence schedule) from each of the bootstrap samples
shows the largest discrepancy of more than 10% over-
all for the 12-hourly A4 schedule (Figure 4).
Approach 3: Comparison of sampling schedules on
simulated data
In the final approach, a simulation study was designed
to assess the effect of more complicated sampling
schedules on parasite clearance estimation. Table A3.3,
Additional file 3 summarizes the performance of the 16
sampling schedules in the simulation study, with results
pooled for all values of HL and P0 considered. That is,
for each schedule 25,000 profiles were used to create
the summary statistics in Table A3.1, Additional file 3
(1,000 from each combination of HL and P0). For each
simulation schedule, the proportion of profiles with AD
(absolute value of the difference) more than one hour be-
tween the HL estimate under the schedule and the “true”HL, and the proportion of profiles with ARD (absolute
value of relative difference) more than 10, 20 and 30%
were calculated.
The worst-performing schedules, in terms of the high-
est ARD, were S4, M1 and S3, having 66, 53 and 52% of
profiles with ARD > 10%; 49, 31 and 26% of profiles with
ARD > 20% and 38, 19 and 13% with ARD > 30% (Table
A3.3, Additional file 3). The best-performing schedule,
in terms of the lowest ARD, for all HL and P0 values
was the six-hourly schedule (S1). The eight-hourly
sampling schedule (S2) had a consistently higher number
of discrepant profiles (ARD > 10%) than S1, but the differ-
ence in the proportion of profiles with discrepant esti-
mates was never more than 6%. More dense sampling
than every 12 hours (S3) was required in the first 24 hours
to accurately estimate HL for profiles with short HL
and/or low initial parasite density. For HL ≤ 3, ARD > 20%
was 19 and 34% for S1 and S3, respectively, compared to
14 and 20% for HL ≥ 4. Similarly for P0 ≤ 10,000 ARD >
20% was 24 and 39% for S1 and S3, respectively, compared
Figure 3 Relative difference (%) between median half-life from alternative schedules A1-A4 and the reference dataset (six-hourly
sampling) for the bootstrap samples, stratified by geometric mean half-life (two, three, four, five, six and seven hours). Boxplots show
the median, interquartile range and range. Panels A, B, C and D correspond to alternative schedules A1, A2, A3 and A4, respectively.
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ules (M1, M2 and M3), M2 had lower ARD > 20% and
ARD > 30% than M1 while M2 performed better or simi-
larly as M3, in terms of ARD > 20% and ARD >30%, except
in simulations where HL = 2 and P0 ≤ 10,000.
For all schedules, except those involving 12 or 24-
hourly sampling (i.e., S3, S4, M1, M2 and M3), the pro-
portion of profiles with an absolute value of difference
(AD) greater than one hour between the estimated HL
and “true” HL increased with HL, but decreased with
the initial parasitaemia. On the other hand, the propor-
tion of profiles with an absolute value of the relative dif-
ference (ARD) greater than 10% (or 20%), was generally
highest for a “true” HL of two hours and then remained
constant or slightly decreased with HL. For schedules
except S4, M2, and M3 the ARD slightly decreased with
initial parasitaemia, but this effect was much less pro-
nounced than for AD.
Among schedules in the simulation study with six or
fewer measurements in the first 48 hours, when HL ≤ 4,the best performing schedules included B1, O1 and M2.
Overall, the B1 and M2 schedules performed slightly
better than O1, with 20, 19 and 22% of profiles with
ARD > 20%, respectively. The three schedules gave simi-
lar results for slow clearing profiles, but not in the case
of very fast clearance. For HL = 2, M2 had the lowest
proportion of profiles with ARD > 10% (37 versus 52 for
B1 and 52% for O1), and ARD > 20% (19 versus 25 and
26%) but similar proportions of profiles with ARD > 30%
(13 versus 12 and 12%). The three schedules gave com-
parable results for high initial parasitaemia, but for low
initial parasitaemia M2 performed better: ARD > 20% for
M2, B1 and O1 were 22, 31 and 33% (P0 = 5,000), re-
spectively compared to 19, 18 and 19% (P0 ≥ 10,000).
Continued sampling after 48 hours was important for
slow clearing profiles. All six-hourly schedules (S1, S1a,
S1b, S1c) gave the same results for HL ≤ 3, due to very
few positive parasitaemias values recorded after 48 hours.
The six-hourly schedules with 12-hourly (S1a) and six-
hourly (S1) measurements after 48 hours gave similar
Figure 4 The proportions of profiles with half-life (HL) more than three hours (in the bootstrap samples with a geometric mean HL = 2
or HL = 3 hours) from the alternative schedules A1-A4 compared with the proportion of profiles with HL > 3 hours from the reference
six-hourly schedule. The blue dashed lines represent y = x, y = x + 10 and y = x-10 lines. Panels A, B, C and D correspond to alternative
schedules A1, A2, A3 and A4, respectively.
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worse. For HL ≥ 4, for example, the proportion of dis-
crepant profiles for S1a and S1 were, 43 and 41%
(ARD > 10%) and 16 and 14% (ARD > 20%), respect-
ively. For S1b and S1c, these values increased to 46
and 45% (ARD > 10%); and 18 and 18% (ARD > 20%),
respectively. When the optimal schedule (O1) was ex-
tended beyond 48 hours, the O1a (12-hourly) sched-
ule gave slightly better estimation results while the
O1b (24-hourly) schedule gave comparable results. All
three schedules gave nearly identical results for HL ≤
3 hours (ARD > 10% and ARD > 20% always within 1%)
while for HL ≥ 4 hours there was a noticeable differ-
ence: the ARD > 20% was 22, 19 and 22% for the O1,
O1a and O1b schedules, respectively, and 48, 45 and
49% for ARD >10%.
When the restriction of the final parasite density being
less than 1,000 per μL was removed from the PCE algo-
rithm, it was clear that the accuracy of the O1 and S1c
schedules was poor if the measured parasitaemia at48 hours was more than 1,000: ARD > 20% was 68% for
O1 when the parasite density at 48 hours exceeded
1,000 compared to 33% for O1a. When the parasite
density at 48 hours was less than 1000 the ARD > 20%
was comparable: 24 and 19% for O1 and O1a, respect-
ively. The same trend was observed for S1c versus S1:
when the parasite density at 48 hours exceeded 1,000
ARD > 20% was 64 and 24% for S1c and S1, respectively
(compared to 20 and 16% when the parasite density at
48 hours was less than 1,000).
Discussion
Surveillance of patient responses to ACT treatment is an
important facet of the WHO Global Plan for Artemisinin
Resistance Containment [4]. The proportion of patients
who remain parasitaemic three days after treatment is a
convenient metric that can warn of possible artemisinin
resistance. However, in depth examination of the rate of
parasite clearance in patients is needed in the context of
efficacy trials of artemisinin derivatives, to determine
Flegg et al. Malaria Journal 2013, 12:411 Page 11 of 14
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tect early changes in parasite clearance. Figure 5 shows
that for HL ≥ 5 hours, the proportion of D3 positive pa-
tients provides a clear indication of diminished response
to artemisinin even with patients with modest initial para-
site densities. However, if the HL is 4 hours, a measure
that is useful as a very early sign of poor response, the pro-
portion of patients still parasitaemic at day 3 is elevated
only in patients with very high initial parasite loads. In
order to provide very early detection of diminished arte-
misinin susceptibility, frequent parasite counts are re-
quired to accurately and reliably estimate parasite
clearance rates, and this is especially true if the goal is to
compare the rates of parasite clearance across different
study sites and times. In this study, the effect of different
sampling schedules on the estimation of parasite HL
was investigated using three approaches: analysis of
real patient data, a bootstrapping algorithm and a
simulation study. Using frequent sampling data from
13 clinical studies (Table 1), HL estimates from four
alternative schedules A1-A4 were calculated and then
compared to the reference HL estimated from six-
hourly data (Table 2). Compared to the reference
schedule, the A1 schedule (zero, six, 12 and 24 hours,
then 12-hourly) performed the best of the four alter-
native schedules, while the A4 schedule (12-hourly)
performed the worst; however, this difference in perform-
ance was most obvious for populations with generally fast
clearing parasites, and lower HLs (Figure 2). Thus, it wasFigure 5 The proportion of profiles at day 3 with a positive
parasite count (more than or equal the limit of detection) as
the initial parasitaemia (P0) varies from 5,000 to 200,000 based
on 1,000 patients generated for each HL and P0 combination,
as per the simulation study. The black, red, blue, green, magenta
and cyan points represent HLs of 2, 3, 4, 5, 6 and 7 hours, respectively.concluded that more frequent sampling is required to de-
fine these fast-clearing populations (Figure 6).
A bootstrapping algorithm was used to study the effect
of different sampling schedules on population estimates
of HL, for populations with different geometric mean
HLs and coefficients of variation. Schedule A1 consist-
ently performed better than the other schedules over a
range of different geometric mean HLs. Its superiority
was greater for profiles with shorter HLs (Figure 3). The
12-hourly A4 schedule performed the worst (Figure 3).
To investigate more complicated sampling schedules
that included a time-point not present in the reference
schedule, a simulation study was performed using “true”
HLs of two, three, four, five and six hours and initial
parasite densities (P0s) of 5,000, 10,000, 50,000, 100,000
and 200,000 per μL. The schedules which performed
worst were 24-hourly sampling (S4), 12-hourly sam-
pling (S3) and the modified 24-hour schedule (M1)
(Table A3.1, Additional file 3), and the best-performing
schedule was six-hourly sampling (S1). The simulation
study confirmed that more dense parasite sampling sched-
ules are required to accurately estimate half-life for pro-
files with short half-life (≤3 hours) and/or low initial
parasite density (≤10,000 per μL). Among schedules in the
simulation study with a limited number of measurements,
when HL ≤ 4 hours, the best performing schedules in-
cluded B1, O1 and M2.
The O1 schedule was identified by Jamsen et al. [28]
as an optimal sampling schedule through a different
methodological approach, and this was also investigated
in the present simulation study. Jamsen et al. used a ro-
bust T-optimal design methodology to allow for discrim-
ination across models that best describe an individual
patient’s parasite-time profile. The design was based on
the constraint that no more than six samples would be
taken per patient within 48 hours of initial treatment.
The T-optimal sampling times (windows) were: 0 (0–1.1),
5.8 (4.0-6.0), 9.9 (8.4-11.5), 24.8 (24.0-24.9), 36.3 (34.8-
37.2) and 48 (47.3-48.0) hours after treatment initiation.
It is interesting and lends support to our results that a
sampling schedule driven by practicalities (B1) turned out
to be a variant of a schedule identified by optimal design
theory (O1).
In the simulation study, sampling after two days was
found to give little additional improvement in parasite
clearance HL estimates for fast clearing parasites (HL ≤
3 hours). This observation is supported by the work of
Nkhoma et al. [16], a study in which the majority of the
profiles had cleared or reached very low parasitaemia
levels by 48 hours. The reduced sampling schedule M2
performed very well in the simulation study; however,
further investigation of this schedule in the field is re-
quired before it can be recommended widely. The
simulation results will be extended to examine factors
Figure 6 Half-life distribution estimates for three datasets with fast, intermediate and slow clearance (subplots A, B and C,
respectively), for the reference (six-hourly, blue) and the alternative A4 (12-hourly, red) sampling schedule. The median HL for each
study is shown with the vertical dashed line (A4 schedule in red, reference schedule in blue). Panels A, B and C correspond to studies with fast,
intermediate and slow clearing parasites, respectively.
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counting method combinations) and patient factors
that affect clearance, notably the potential interaction
between parasite clearance and clinical immunity. It is
also important to recognize that high quality quanti-
tative microscopy to measure the parasite density in
the peripheral blood is essential for accurate estima-
tion of parasite clearance rates.
The clinical phenotype of slow P. falciparum clearance
is likely to remain a critical indictor of artemisinin resist-
ance to be correlated with molecular markers when they
are identified and validated. Furthermore, in the context
of detecting the emergence and spread of artemisinin re-
sistance, it is important to establish reliable baselines of
parasite clearance for the different ACT available. Indeed,
depending on the type and dosage of artemisinin deriva-
tives in the various ACT (eg, artemether 1.7 mg/kg body
weight in fixed-dose combination (FDC) of artemether-
lumefantrine per dose; artesunate 4 mg/kg in FDC of
artesunate-amodiaquine per day; and dihydroartemisinin
2 mg/kg in FDC of dihydroartemisinin-piperaquine), and
the impact of the partner drugs, parasite clearance profiles
may vary substantially. Hence, accurate and reliable esti-
mation of parasite clearance rates is essential to monitor
changes in artemisinin susceptibility within and between
malaria-endemic regions. In investigating the effect of
different sampling schedules on the accuracy of HL
estimation, this study has shown that HL is best esti-
mated by including samples at six and 12 hours (A1),
and that 12-hourly sampling may be satisfactory in
patients with slow-clearing parasites. It is particularly
challenging to accurately estimate the HL in profiles
with fast parasite clearance and low initial parasitedensity, the conditions usually encountered in high-
transmission areas where individuals have significant
levels of immunity.
Conclusions
This study reveals important insights on sampling designs
for accurate and reliable estimation of P. falciparum HL
following treatment with artesunate alone or in combin-
ation with a partner drug. Including a parasite measure-
ment at six hours is important, especially in regions with
unknown P. falciparum susceptibility to artemisinins.
Schedules with measurements at times (windows) of 0
(0–2), 6 (4–8), 12 (10–14), 24 (22–26), 36 (34–36)
and 48 (46–50) hours, or at six, seven (two samples
from 5–8), 24, 25 (two samples from 23–26), 48 and 49
(two samples from 47–50) hours, until negative are rec-
ommended. If the measured parasitaemia at two days ex-
ceeds 1,000 per μL, continued sampling at least once a
day is suggested. A measure at 72 hours should be consid-
ered if the goal is to assess drug efficacy overall, and to
conform to existing recommendations.Additional files
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